The established NSCLC MDR cell lines are promising models to understanding mechanisms associated with MDR and exploiting collateral sensitivity approaches to overcome MDR in NSCLC.

Paclitaxel resistance was successfully overcome in a xenograft model in which paclitaxel-resistant A549/TxR cells were used in BALB/c nude mice, as expected...In vitro, compound 17 potently induced immunogenic cell death in A549 cells at 80 nM, outperforming the reference drug doxorubicin at 200 nM. In the C57BL/6 mouse LLC model, compound 17 achieved a remarkable 81.6% tumor growth inhibition rate and effectively promoted the infiltration of CD4+ and CD8+ T cells into the tumor microenvironment and increased the levels of multiple serum immune factors. These results highlight 17 as a promising candidate for the development of novel chemoimmunotherapy strategies.

P2/3, N=160, Not yet recruiting, Guangdong Provincial People's Hospital

P2, N=50, Completed, Damanhour University | Recruiting --> Completed

P1, N=140, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2027 --> Mar 2027 | Trial primary completion date: Sep 2027 --> Jan 2027

A therapy experiment in immunocompetent mice bearing low FAP-expressing tumors showed that the combination with L19-hIL2 potentiated the antitumoral activity of 177Lu-OncoFAP-23 and OncoFAP-GlyPro-MMAE. These results provided the motivation for the clinical development of these combinations for treating FAP-positive solid tumors.

CRISPR-mediated KRAS knockdown in SKOV-3 cells dramatically altered three-dimensional spheroid morphology, reducing the average area six-fold, and significantly enhanced sensitivity to both cisplatin and paclitaxel in 3D cultures, where paclitaxel resistance was completely reversed. In KRAS-amplified Kuramochi cells (representing high-grade serous ovarian carcinoma), BI2865 enhanced paclitaxel efficacy, despite greater baseline chemoresistance. These findings establish KRAS as a promising chemosensitization target in ovarian cancer, with particular potential for taxane-based combination therapies.

In contrast, SiHa spheroids represented selective responses: MSC-exosome pretreatment did not enhance sensitivity to paclitaxel-cisplatin but improved responsiveness to paclitaxel-carboplatin, particularly within the spheroid core. Overall, MSC-exosome pretreatment exerts cell type and drug-specific effects in CC spheroids, supporting their potential to modulate chemotherapy response.

In MKN-45 cells, merestinib increased the expression of pro-apoptotic proteins and decreased phosphorylation of c-Met, EGFR, IGF-1R, ERK, and AKT. These results indicate that combining merestinib with nab-paclitaxel may represent a promising therapeutic strategy to improve outcomes for patients with GAC.

RTN4IP1 expression was further linked to features of the tumor immune microenvironment and to differential responses to Tamoxifen and Paclitaxel; inhibition of RTN4IP1 was associated with greater drug sensitivity, while overexpression coincided with reduced response. Together, these findings indicate that RTN4IP1 is closely associated with BC progression, prognosis, and treatment response, supporting its potential relevance as a biomarker and a candidate target for further investigation.

4-hydroxytamoxifen enhances stemness through the NRP/ERRα pathway to enhance breast cancer cell PTX resistance and metastasis.

P2, N=60, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University